The REPViT brand was created in 2020 to market and commercialise an innovative diagnostic platform for both virus and bacterial infections based on a proprietary IP (EP20382499.0).
The aim of REPViT is to offer fast, affordable and easy to use diagnostic solutions for consumers and professionals to detect SARS-CoV-2, Influenza and other viruses and bacteria at home and on the go, in less than 15 minutes using saliva.
The REPViT device concept is a rapid Nucleic Acid Test (NAT) equivalent to PCR in a single-use handheld over the counter test format, similar to a pregnancy test.
The REPViT technology does not require any manufacturing that is not available at large scale (i.e. no electronics, microfluidics, optics etc), does not use enzymes and does not require large laboratory equipment or specialist staff. This allows for rapid mass production and deployment of the test to meet demand in order to contain even very virulent infections.
The REPViT technology is easy to use, not sensitive to temperature and can be prepared in a home-test kit format, applied in all geographies, and most circumstances such as work, school, transport, hospital, care home or football stadium. It can be adapted to detect additional virus based, or bacterial, infectious diseases.
Due to the simplicity of handling and application of the REPViT test, it can be sold as a B2B product to doctors and hospitals or as B2C in form of a home-test kit through chemists or pharmacies and drugstores. Its comfortable application (using saliva from spitting and without intrusive nasal or buccal swabbing) will make it the preferred test.
The low production cost of the REPViT tests allows for the test to be used by all income levels and a number of tests can be used in sequence
The REPViT platform technology is easily adapted from the initial Covid-19/Influenza test and subsequently to other infectious diseases caused by viruses and bacteria.
This will allow governments, professionals and individuals to work together effectively to contain infectious diseases more efficiently and keep infection rates low.
Chief Executive Officer (CEO)
Kevin has degrees in commerce and international finance and >30 years commercial experience as senior tax accountant for Deloitte and PWC, and project leader for Arthur Anderson and EY.
Operating at Senior Management level within several global financial organisations, Kevin has extensive experience in business development and operational management. With a focus on Project Management and process improvement, Kevin has worked across the world, at times managing up to 35 different country teams on multistate cross border projects.
Founder & Chief Scientific Officer (CSO)
Charles did his doctorate from Institute of Virology (Oxford University), where he patented novel viral diagnostic technology for West Nile Virus. He later migrated to cancer research at John Radcliffe Hospital, Oxford. Author of >110 publications, he is a pioneer of biomarkers in bodily fluids.
Daniel Maitland (MA)
Co-founder & IT consultant
Director at Opus Energy. With 10+ years of experience in IT and successful growth and exit in multiple companies. Founding director of Oxford Cloud Technology.
Prof. Peter J. Dobson OBE
Pete was Director of Oxford University’s Begbroke Science Park until 2013, and the Strategic Advisor on Nanotechnology to the UK Research Councils. He founded Oxonica, Oxford Biosensors and Oxford NanoSystems and has specific expertise in nanoparticles, nanostructures, optoelectronics and biosensors
Anton Eratt (MSc)
Commercial & Market Consultant
Anton was the founder and chairman of VPlus Network ltd. He later founded and was the CEO of CCIE ltd. He has a strong background in business development and account development. His wide range of experience includes, commercial leadership, management of the overall operations, product development, marketing, communications, and logistics. Anton has significant experience as the senior account lead with varicose NHS trusts as well as central Government’s clients.
María Armesto (Dphil)
Maria did her first degree and masters at the University of Oviedo. Later she obtained her doctorate (Dphil) from the University of Oxford at the institute of virology specializing on the development of new therapies for Rna viruses. Afterwards, she spent seven years as a senior scientist in IAH Compton within the coronavirus group.